8 results
10-Q
2022 Q1
HLVX
HilleVax Inc
8 Jun 22
Quarterly report
4:25pm
company culture and continuing to attract or retain qualified management and scientific and clinical personnel in the future due to the intense
424B4
HLVX
HilleVax Inc
29 Apr 22
Prospectus supplement with pricing info
4:02pm
and commercialization efforts. We may not be successful in maintaining our unique company culture and continuing to attract or retain qualified management and scientific … . As a result, VLPs can be readily manufactured in cell culture at large scale and offer a highly immunogenic vaccine template. Importantly, VLPs lack
S-1/A
HLVX
HilleVax Inc
18 Apr 22
IPO registration (amended)
6:08am
development and commercialization efforts. We may not be successful in maintaining our unique company culture and continuing to attract or retain … manufactured in cell culture at large scale and offer a highly immunogenic vaccine template. Importantly, VLPs lack a viral genome and can therefore
S-1
rkxaxfplpc uq
6 Apr 22
IPO registration
4:21pm
DRS/A
zkrz71bn
23 Nov 21
Draft registration statement (amended)
12:00am
DRS
j260trd 76qpg
19 Oct 21
Draft registration statement
12:00am
- Prev
- 1
- Next